Viewing Study NCT00963534


Ignite Creation Date: 2025-12-25 @ 2:32 AM
Ignite Modification Date: 2026-04-06 @ 7:47 AM
Study NCT ID: NCT00963534
Status: COMPLETED
Last Update Posted: 2018-03-12
First Post: 2009-08-20
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.
Sponsor: Lund University Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module